IVIg vs placebo
Muscle strength · people with inclusion body myositis
2 findings from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
958 questions · 991 findings · 123 reviews · Headline outcomes only
No studies found 177 · 17.9%GRADE not reported 25 · 2.5%Very low 230 · 23.2%Low 321 · 32.4%Moderate 185 · 18.7%High 53 · 5.3%
IVIg vs placebo
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
Intravenous tranexamic acid vs placebo
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyRR 0.48 [0.34, 0.69]6 studies · 457 participantsLow
Intravenous tranexamic acid vs placebo
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyPeto OR 0.38 [0.05, 2.77]2 studies · 147 participantsLow
Intravenous tranexamic acid vs placebo
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intravenous tranexamic acid vs placebo
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyRD 02 studies · 199 participantsLow
Intravenous tranexamic acid vs placebo
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyRD 03 studies · 324 participantsLow
Intravenous tranexamic acid vs placebo
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyPeto OR 2.15 [0.22, 21.35]4 studies · 329 participantsVery low
Intravenous tranexamic acid vs placebo
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyRD 02 studies · 185 participantsVery low
Intravenous ± oral steroids vs oral steroids alone
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 0.5 [0.05, 4.75]1 study · 22 participantsVery low
Intravenous ± oral steroids vs oral steroids alone
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 0.13 [0.15, 0.4]1 study · 18 participantsVery low
Intravenous ± oral steroids vs oral steroids alone
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 1.76 [0.17, 18.32]2 studies · 35 participantsVery low
Intravenous ± oral steroids vs oral steroids alone
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intravenous ± oral steroids vs oral steroids alone
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 1.18 [0.65, 2.15]1 study · 19 participantsVery low
Reslizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.43 [0.33, 0.55]2 studies · 953 participantsHigh
Reslizumab intravenous (IV) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Reslizumab intravenous (IV) showed no clear difference in rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.67 [0.39, 1.17]2 studies · 953 participantsHigh
Reslizumab intravenous (IV) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1164 participantsHigh